TC BioPharm, a biotechnology company registered in Scotland and listed on The Nasdaq Stock Market under the symbol TCBP, filed a Form 8-K with the United States Securities and Exchange Commission on March 14, 2024. The report indicates that the company's general meeting of shareholders, initially announced on February 19, 2024, was held as scheduled. However, during the meeting, the chairman exercised their vested powers, with the consent of the attendees, to adjourn the meeting to a later date and location that will be determined and announced in the future. TC BioPharm is identified as an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.

TC BioPharm, a biotechnology company registered in Scotland and listed on The Nasdaq Stock Market under the symbol TCBP, filed a Form 8-K with the United States Securities and Exchange Commission on March 14, 2024. The report indicates that the company's general meeting of shareholders, initially announced on February 19, 2024, was held as scheduled. However, during the meeting, the chairman exercised their vested powers, with the consent of the attendees, to adjourn the meeting to a later date and location that will be determined and announced in the future. TC BioPharm is identified as an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.